Site updated at Wednesday, 22 June 2016

Living with Dementia


Eli Lilly Announces FDA Approval of Amyvid For Alzheimer’s Assessment

Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced the U.S. Food and Drug Administration (FDA) approval of Amyvid™, a radioactive diagnostic agent indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer’s Disease and other causes… Eli Lilly Announces FDA Approval of Amyvid For Alzheimer’s Assessment   

FDA OKs Agent to Differentiate Alzheimer’s

The FDA has approved the radioactive diagnostic agent florbetapir (Amyvid) for evaluation of the causes of cognitive decline, including Alzheimer’s disease, according to Eli Lilly, developer of the compound.

Florbetapir is used in conjunction with positron emission tomography to evaluate the burden of amyloid plaques in the brain, according to Daniel Skovronsky, MD, PhD,… FDA OKs Agent to Differentiate Alzheimer’s   

Enid and George - Life with dementia

memory capacity1 - prion disease1 - parkinson's disease59 - lewy body1 - cotard's syndrome1 - familial alzheimer's disease2 - abnormal tau protein1 - mind diet1 - symptoms of parkinson's3 - aripiprazole1 - parkinson's risk2 - medical history1 - mcr1 - brain health1 - faseb journal1 - long-term dementia1 - disease progression1 - idiocy1 - cognitive impairment10 - alzheimer's drugs4 - learning1 - trouble sleeping1 - alzheimer's disease prevention1 - stages of atherosclerosis1 - microhemmorhage1 - alzheimer's plan1 - restlessness1 - long-term cognitive changes1 - arts health institute1 - diagnosis of dementia1 -